Diagnosis | Jotup

CorVista Health to Present New Data on the Use of Machine Learning as a Non-Invasive Point-of-Care Rule-out Test for Heart Failure at ACC 2024

Retrieved on:

Sunday, April 7, 2024

The CorVista System is the world’s first non-invasive point-of-care solution for evaluating the presence of coronary artery disease and pulmonary hypertension.

Key Points:

The CorVista System is the world’s first non-invasive point-of-care solution for evaluating the presence of coronary artery disease and pulmonary hypertension.
Timely identification of left ventricular dysfunction plays a pivotal role in effective heart failure management, however, measuring elevated LVEDP currently relies on invasive left heart catheterization.
Sc.D., Executive Vice President and Chief Scientific Officer, CorVista Health.
“We believe the CorVista System can uniquely and effectively address these important unmet needs for people living with cardiovascular disease, especially in rural and underserved populations.”

PredxBio and PictorLabs Forge Strategic Partnership to Advance Cancer Research and Diagnostics with Next Generation Spatial Analytics

Retrieved on:

Tuesday, April 9, 2024

Diagnosis, Science, Partnership, Patient, Biomarker, Research, Tumor microenvironment, Artificial intelligence, Cancer, Doctor of Philosophy, Biology, Pathology, LOS, College of Engineering (KNUST), Medical imaging

PITTSBURGH and LOS ANGELES, April 9, 2024 /PRNewswire-PRWeb/ -- PredxBio, Inc., a leader in spatially intelligent biology, and PictorLabs, Inc., a leading digital pathology firm pioneering AI-powered virtual staining technology, are pleased to announce a transformative partnership aimed at revolutionizing cancer research, diagnosis, and treatment.

Key Points:

PredxBio is renowned for its innovative approach to unraveling the intricate circuitries of the tumor microenvironment and leveraging Explainable AI to gain deeper insights into cancer biology.
"This partnership represents a significant step forward in our collective efforts to transform cancer diagnostics and treatment," added Yair Rivenson, PhD, CEO of PictorLabs.
The partnership between PredxBio and PictorLabs represents a powerful synergy between two innovative companies dedicated to pushing the boundaries of science and technology.
By leveraging their respective strengths, they aim to accelerate the development of novel diagnostic tools and therapies for cancer patients worldwide.

Apixio Partners With Vim to Deliver AI-Powered Insights at the Point of Care

Retrieved on:

Tuesday, April 9, 2024

Diagnosis, Health, Friction, Documentation, Partnership, Risk, SAN, Electronic health record, Workflow, EHR, Mining

SAN MATEO, Calif., April 9, 2024 /PRNewswire/ -- Apixio, a leading healthcare data and analytics company, announces a strategic partnership with Vim, a leading point-of-care connection platform, to enhance accurate condition capture during the patient visit and improve patient care. This initiative leverages Apixio's expertise in analyzing structured and unstructured data for enhanced risk adjustment and enables seamless integration within clinical workflows. Apixio's insights include sophisticated analytics and reporting capabilities to monitor performance, promote provider participation, and identify educational opportunities. The collaboration features user-friendly tools that fit effortlessly into provider workflows, fostering greater adoption and engagement.

Key Points:

Apixio's insights include sophisticated analytics and reporting capabilities to monitor performance, promote provider participation, and identify educational opportunities.
The healthcare industry is transforming significantly, shifting from retrospective to prospective risk adjustment and/or hybrid models to manage patient care and financial outcomes better.
Prospective risk adjustment allows healthcare providers and payers to assess patient risk more accurately and timely, improving care management and economic performance.
However, this shift presents several challenges, including seamlessly integrating insights into EHR systems and ensuring that these insights are delivered efficiently and effectively to clinicians at the point of care.

Association for Diagnostics & Laboratory Medicine (formerly AACC) survey of clinical labs finds that FDA's proposed laboratory developed tests rule would hinder pediatric care

Retrieved on:

Tuesday, April 9, 2024

Hospital, Diagnosis, Disability, Risk, AACC, CLIA, Clinical Laboratory, Brain damage, Medical laboratory, Medicare, FDA, CMS, Health, Legislation, Food, Pharmaceutical industry

View the full survey results here: https://www.myadlm.org/lp/ldts-survey

Key Points:

View the full survey results here: https://www.myadlm.org/lp/ldts-survey
Laboratory developed tests are tests that clinical labs create and perform in-house to meet the needs of their local patient populations.
These tests are currently regulated by the Centers for Medicare & Medicaid Services (CMS) via the Clinical Laboratory Improvement Amendments (CLIA).
In the first week, 140 U.S. clinical labs responded to the survey, 87% of which said they perform laboratory developed tests.
ADLM's survey findings underscore the fact that placing these tests under additional FDA oversight would undermine care for children across the U.S."

Navigate BioPharma Services, Inc. announces collaboration with RareCyte, Inc. to provide enhanced spatial biology capabilities using the Orion™ Platform

Retrieved on:

Tuesday, April 9, 2024

Diagnosis, Digital pathology, Pathology, Associate, Partnership, Biomarker, Tumor microenvironment, Orion, Navigation, Medical imaging

This collaboration aims to leverage the complementary expertise of both companies to provide end-to-end spatial biology services for pharmaceutical and clinical institutions worldwide.

Key Points:

This collaboration aims to leverage the complementary expertise of both companies to provide end-to-end spatial biology services for pharmaceutical and clinical institutions worldwide.
Navigate BioPharma provides years of experience in developing high-plex imaging assays and creating highly customized biomarker solutions for immuno-oncology and oncology clinical trials.
The Orion platform enables Navigate BioPharma to expand the degree of customization and depth of biomarker data that can be assessed to inform clinical decisions.
Over the past years, Navigate BioPharma has developed and validated over 125 unique multiplex immunofluorescence (mIF) assays.

HealthTrackRx Appoints Leading Healthcare Expert Dr. Steven Goldberg as Chief Medical Officer

Retrieved on:

Tuesday, April 9, 2024

DENTON, Texas, April 9, 2024 /PRNewswire/ -- HealthTrackRx, the nation's premier molecular diagnostic testing laboratory, today announced the appointment of Steven Goldberg, MD, MBA, as its Chief Medical Officer (CMO).

Key Points:

DENTON, Texas, April 9, 2024 /PRNewswire/ -- HealthTrackRx, the nation's premier molecular diagnostic testing laboratory, today announced the appointment of Steven Goldberg, MD, MBA, as its Chief Medical Officer (CMO).
In the newly created role, Dr. Goldberg will lead the Company's partnership with payors, clinicians, and industry to enhance access to faster, better diagnostics.
A distinguished physician and respected healthcare innovator, Dr. Goldberg previously served as Chief Health Officer and Vice President of Medical Affairs at Quest Diagnostics and, preceding that, more than a decade in leading roles of several major health plans, including Chief Medical Officer at WellCare Health Plans, Senior Medical Director at Coventry Health Care, Chief of Medical Affairs at Express Scripts, Corporate Medical Director, Clinical Policy and Quality at Humana, Regional Chief Medical Officer at Excellus BCBS, Network Medical Director at Aetna Health Plans, and Medical Director at Kaiser Permanente NE.
"HealthTrackRx is transforming antibiotic stewardship protocols and helping payors and health plans manage spending by eliminating unnecessary tests, misdiagnosis, and ineffective antibiotic treatment.

Global A.I. Healthcare Market Expected to Expand at CAGR of 36.4% From 2024 to 2030

Retrieved on:

Tuesday, April 9, 2024

PALM BEACH, Fla., April 9, 2024 /PRNewswire/ -- Experts universally see that the AI in the healthcare market will continue to reach new highs throughout this decade. A report from Grand View Research said that the global AI in healthcare market size was estimated at USD 22.45 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 36.4% from 2024 to 2030. The report said: "Growing datasets of patient health-related digital information, increasing demand for personalized medicine, and rising need to reduce care expenses are some major drivers of market growth. The rising global geriatric population, changing lifestyles, and increasing prevalence of chronic diseases have contributed to a growth in demand for diagnosing and improved understanding of diseases in their initial stages. Artificial Intelligence (AI) and machine learning (ML) algorithms are being widely adopted and integrated into healthcare systems to accurately predict diseases in their early stage based on historical health datasets. Furthermore, deep learning technologies, predictive analytics, content analytics, and natural language processing (NLP) tools are enabling care professionals to diagnose patient's underlying health conditions at an earlier stage. The COVID-19 pandemic positively influenced the demand for AI technologies and unearthed the potential of these advanced technologies. Healthcare systems widely adopted these technologies in the rapid diagnosis and detection of different virus strains and utilized personalized information in improving the management of the outbreak. AI/ML algorithms were utilized in the diagnosis sector wherein these technologically driven modules were trained with datasets of chest CT images, symptoms, pathological findings, and exposure history to diagnose COVID-19-positive patients rapidly and accurately." Active tech companies in the markets this week include: Avant Technologies, Inc. (OTCQB: AVAI), NVIDIA Corporation (NASDAQ: NVDA), SoundHound AI, Inc. (NASDAQ: SOUN), CXApp Inc. (NASDAQ: CXAI), Marvell Technology, Inc. (NASDAQ: MRVL).

Key Points:

A report from Grand View Research said that the global AI in healthcare market size was estimated at USD 22.45 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 36.4% from 2024 to 2030.
The COVID-19 pandemic positively influenced the demand for AI technologies and unearthed the potential of these advanced technologies.
Healthcare systems widely adopted these technologies in the rapid diagnosis and detection of different virus strains and utilized personalized information in improving the management of the outbreak.
This potent combination empowers healthcare and life sciences organizations to navigate the complexities of data and system interoperability with unprecedented efficiency.

Global A.I. Healthcare Market Expected to Expand at CAGR of 36.4% From 2024 to 2030

Retrieved on:

Tuesday, April 9, 2024

PALM BEACH, Fla., April 9, 2024 /PRNewswire/ -- Experts universally see that the AI in the healthcare market will continue to reach new highs throughout this decade. A report from Grand View Research said that the global AI in healthcare market size was estimated at USD 22.45 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 36.4% from 2024 to 2030. The report said: "Growing datasets of patient health-related digital information, increasing demand for personalized medicine, and rising need to reduce care expenses are some major drivers of market growth. The rising global geriatric population, changing lifestyles, and increasing prevalence of chronic diseases have contributed to a growth in demand for diagnosing and improved understanding of diseases in their initial stages. Artificial Intelligence (AI) and machine learning (ML) algorithms are being widely adopted and integrated into healthcare systems to accurately predict diseases in their early stage based on historical health datasets. Furthermore, deep learning technologies, predictive analytics, content analytics, and natural language processing (NLP) tools are enabling care professionals to diagnose patient's underlying health conditions at an earlier stage. The COVID-19 pandemic positively influenced the demand for AI technologies and unearthed the potential of these advanced technologies. Healthcare systems widely adopted these technologies in the rapid diagnosis and detection of different virus strains and utilized personalized information in improving the management of the outbreak. AI/ML algorithms were utilized in the diagnosis sector wherein these technologically driven modules were trained with datasets of chest CT images, symptoms, pathological findings, and exposure history to diagnose COVID-19-positive patients rapidly and accurately." Active tech companies in the markets this week include: Avant Technologies, Inc. (OTCQB: AVAI), NVIDIA Corporation (NASDAQ: NVDA), SoundHound AI, Inc. (NASDAQ: SOUN), CXApp Inc. (NASDAQ: CXAI), Marvell Technology, Inc. (NASDAQ: MRVL).

Key Points:

A report from Grand View Research said that the global AI in healthcare market size was estimated at USD 22.45 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 36.4% from 2024 to 2030.
The COVID-19 pandemic positively influenced the demand for AI technologies and unearthed the potential of these advanced technologies.
Healthcare systems widely adopted these technologies in the rapid diagnosis and detection of different virus strains and utilized personalized information in improving the management of the outbreak.
This potent combination empowers healthcare and life sciences organizations to navigate the complexities of data and system interoperability with unprecedented efficiency.

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

Retrieved on:

Tuesday, April 9, 2024

Diagnosis, ALS, Biomarker, Research, Acquisition, Patient, Investment

This agreement provides NeuroSense with access to Lonza's unparalleled, state-of-the-art extracellular vesicles expertise and capabilities quickly and on an 'on-demand' basis, without further commitments.

Key Points:

This agreement provides NeuroSense with access to Lonza's unparalleled, state-of-the-art extracellular vesicles expertise and capabilities quickly and on an 'on-demand' basis, without further commitments.
NeuroSense will leverage its extensive experience in biomarker utilization in neurodegenerative diseases.
Our 'Dev-on-Demand' solution provides NeuroSense with access to expert scientists working in state-of-the-art laboratories for their development activities.
The team and platform make Lonza the partner of choice for NeuroSense to identify exosomes-based biomarkers."

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

Retrieved on:

Tuesday, April 9, 2024

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.

Key Points:

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.
With the theme "Technologic Innovation, Scientific Discovery, Translational Application", TICSSO-2 focused on the latest advances in single-cell and spatial omics.
On March 31st and April 1st were four online international forums, with one specifically for young researchers.
TICSSO-2 is hailed as the largest, most influential, and highest academic conference in the field of single-cell and spatial omics in the world.